23rd November 2011 – Ascribe, the leading provider of integrated clinical solutions, announces today that it has undertaken a joint initiative with Microsoft® to tackle the issue of venous thromboembolism (VTE). According to the NHS, VTE causes 25,000 avoidable deaths a year and costs the taxpayer £640m. (http://www.guardian.co.uk/society/2007/apr/20/health) 

“The All-Party Parliamentary Thrombosis Group (APPTG) has recommended that a CQUIN-compliant electronic VTE risk assessment template is used by clinicians. In fact, Electronic VTE assessment solutions are cited to raise compliance on VTE assessment from 30% to over 90% in 1 year”.
(Source: Whittington NHS Trust)

Whilst the government has made VTE a clinical priority, recent research by E-Health Insider (EHI) indicated that there are a still considerable number of trusts who are not complying with current CQUIN standards, and more than 80% of trusts surveyed still undertake the burden of collecting VTE assessments manually.  Not only is this a patient safety issue, it also impacts upon the clinical productivity and trust finances.

Ascribe Consulting, in partnership with Microsoft, has developed a clinically based VTE solution, which enables VTE compliance and management to meet and exceed current CQUIN targets.

An important component of the solution is its real-time reporting, this enables more responsive patient care and greater clarity of VTE compliance at multiple levels: the hospital, the ward and patient level.  Lack of compliance will quickly alert clinicians and managers, using mobile technology. Patient level data can be quickly reviewed for root cause analysis, and our business intelligence dashboard provides real time reporting for management and audit purposes.

To promote this VTE risk-assessment & root cause analysis solution, Ascribe & Microsoft are hosting a series of webinars to VTE leads & Haematology Clinicians. The first, entitled, “VTE - Beyond CQUIN targets” will be held on the 14th December 2011. To register for this webinar or to request more information, please contact Urszula Bennett at [email protected] or Simon Josephs at [email protected].